Tray Thomas sold $200K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,051 shares of INCYTE CORP (INCY) at $97.35 ($0.20M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
medium confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings under a 10b5-1 plan; it does not include guidance, litigation, or operational updates.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but the 10b5-1 structure makes it unlikely to drive a durable repricing by itself.

03

What to watch

Insider sales can be offset by other insider buys or option exercises not shown here; also, the filing does not reveal intent beyond the pre-arranged plan.

Relevance 3/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-26

Background

This is an SEC Form 4 insider transaction disclosure for Incyte, reported by Tray Thomas (Principal Accounting Officer).

Company-level read

Ticker impact

$INCYNeutralMedium confidence
Context

Incyte Form 4 shows Tray Thomas sold 2,051 shares at $97.35 on a 10b5-1 plan, disclosing $199,664.85 in insider sales.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and is time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 schedule and should not be treated as bearish signal.

Key entities

  • Incyte Corp

    Subject of the Form 4 insider transaction disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INCYHighAI 8/10

Incyte Advances Pancreatic and Colorectal Cancer Drug Trials

Incyte Corp. (INCY) is advancing two cancer treatments, INCB161734 and INCA33890, into late-stage trials after early results showed promising responses in pancreatic and colorectal cancers. INCB161734, combined with chemotherapy, showed high response rates in pancreatic cancer, while INCA33890 demonstrated activity in colorectal cancer. The company plans Phase 3 trials with topline results expected in 2028 and 2029, respectively.

$INCYMed

Incyte wins Indian patent injunction just weeks before expiration

Incyte secured an interim injunction in India against Melody Healthcare regarding its ruxolitinib patent, just 11 weeks before the patent's expiration. The Delhi High Court ruled in favor of interim protection due to the patent's remaining validity and lack of competing commercial launch. According to the court, this ruling highlights the availability of interim protection against threatened infringement before a rival's commercial launch.

$INCYMedAI 8/10

Ruxolitinib Cream Well Tolerated in Children With AD

A phase 3 study found that ruxolitinib cream was well tolerated and maintained disease control in children aged 2-11 with mild to moderate atopic dermatitis (AD) over 44 weeks. The study, funded by Incyte Corporation, showed 79.5% of children on 0.75% strength and 72.3% on 1.5% had clear or almost clear skin at week 52. Common side effects included upper respiratory tract infection and neutropenia. The authors suggest ruxolitinib cream as a potential corticosteroid-free treatment option for AD.